ProQR Therapeutics N.V. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
167.10
532.30
1,351.80
1,202.40
1,124.30
Gross Income
-
167.10
532.30
1,351.80
1,202.40
1,124.30
SG&A Expense
4,454.20
22,082.70
32,999.30
44,445.90
46,163.00
48,488.90
EBIT
4,454.20
22,249.80
33,531.60
45,797.70
47,365.40
49,613.20
Non Operating Income/Expense
154.00
6,272.80
10,313.00
2,838.50
1,324.20
6,817.80
Interest Expense
50.40
351.50
438.00
595.10
672.20
955.60
Pretax Income
4,318.70
16,085.80
23,101.00
43,255.60
49,260.30
43,751
Income Tax
-
-
-
-
2.30
1.20
Consolidated Net Income
4,318.70
16,085.80
23,101.00
43,255.60
49,262.50
43,752.20
Net Income
4,318.70
16,085.80
23,101.00
43,255.60
49,219.70
43,525.70
Net Income After Extraordinaries
4,318.70
16,085.80
23,101.00
43,255.60
49,219.70
43,525.70
Net Income Available to Common
4,318.70
16,085.80
23,101.00
43,255.60
49,219.70
43,525.70
EPS (Basic)
0.19
1.45
0.99
1.85
1.94
1.28
Basic Shares Outstanding
23,338.20
11,082.80
23,343.30
23,346.50
25,374.80
34,052.50
EPS (Diluted)
0.19
1.45
0.99
1.85
1.94
1.28
Diluted Shares Outstanding
23,338.20
11,082.80
23,343.30
23,346.50
25,374.80
34,052.50
EBITDA
4,422.30
22,082.70
32,999.30
44,445.90
46,163.00
48,488.90
Non-Operating Interest Income
31.90
242.70
555.60
298.70
101.50
-
Minority Interest Expense
-
-
-
-
42.90
226.50
About ProQR Therapeutics
View Profile
